<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">69734</article-id><article-id pub-id-type="doi">10.7554/eLife.69734</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group></article-categories><title-group><article-title>Dysregulated heparan sulfate proteoglycan metabolism promotes Ewing sarcoma tumor growth</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-237781"><name><surname>Vasileva</surname><given-names>Elena</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-237783"><name><surname>Warren</surname><given-names>Mikako</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-237782"><name><surname>Triche</surname><given-names>Timothy J</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-101786"><name><surname>Amatruda</surname><given-names>James F</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-9901-2137</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution content-type="dept">Cancer and Blood Disease Institute</institution>, <institution>Children's Hospital of Los Angeles</institution>, <addr-line><named-content content-type="city">Los Angeles</named-content></addr-line>, <country>United States</country></aff><aff id="aff2"><institution content-type="dept">Division of Pathology and Laboratory Medicine</institution>, <institution>Children's Hospital of Los Angeles</institution>, <addr-line><named-content content-type="city">Los Angeles</named-content></addr-line>, <country>United States</country></aff><aff id="aff3"><institution content-type="dept">Department of Pediatrics</institution>, <institution>Children's Hospital of Los Angeles</institution>, <addr-line><named-content content-type="city">Los Angeles</named-content></addr-line>, <country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-109554"><name><surname>Postovit</surname><given-names>Lynne-Marie</given-names></name><role>Reviewing editor</role><aff><institution>University of Alberta</institution>, <country>Canada</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>jamatruda@chla.usc.edu</email> (JA);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>14</day><month>03</month><year>2022</year></pub-date><volume>11</volume><elocation-id>e69734</elocation-id><history><date date-type="received"><day>24</day><month>04</month><year>2021</year></date><date date-type="accepted"><day>13</day><month>03</month><year>2022</year></date></history><permissions><copyright-statement>Â© 2022, Vasileva et al</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Vasileva et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-69734-v1.pdf"/><abstract><p>The Ewing sarcoma family of tumors is a group of malignant small round blue cell tumors (SRBCTs) that affects children, adolescents, and young adults. The tumors are characterized by reciprocal chromosomal translocations that generate chimeric fusion oncogenes, the most common of which is EWSR1-FLI1. Survival is extremely poor for patients with metastatic or relapsed disease, and no molecularly-targeted therapy for this disease currently exists. The absence of a reliable genetic animal model of Ewing sarcoma has impaired investigation of tumor cell/microenvironmental interactions <italic>in vivo</italic>. We have developed a new genetic model of Ewing sarcoma based on Cre-inducible expression of human <italic>EWSR1-FLI1</italic> in wild type zebrafish, which causes rapid onset of SRBCTs at high penetrance. The tumors express canonical EWSR1-FLI1 target genes and stain for known Ewing sarcoma markers including CD99. Growth of tumors is associated with activation of the MAPK/ERK pathway, which we link to dysregulated extracellular matrix metabolism in general and heparan sulfate catabolism in particular. Targeting heparan sulfate proteoglycans with the specific heparan sulfate antagonist Surfen reduces ERK1/2 signaling and decreases tumorigenicity of Ewing sarcoma cells <italic>in vitro</italic> and <italic>in vivo</italic>. These results highlight the important role of the extracellular matrix in Ewing sarcoma tumor growth and the potential of agents targeting proteoglycan metabolism as novel therapies for this disease.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Zebrafish</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>U54CA231649-01</award-id><principal-award-recipient><name><surname>Amatruda</surname><given-names>James F</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution>1 Million 4 Anna</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Amatruda</surname><given-names>James F</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocols of the University of Southern California, protocol number 21150.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>Proteomics data have been deposited in Dryad (doi:10.5061/dryad.x95x69pj8)</p><p>The following datasets were generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>Vasileva E</collab><collab>Amatruda JF</collab></person-group><year iso-8601-date="2021">2021</year><source>Proteomics analysis of normal and EWSR1-FLI1-expressing embryos/tissue</source><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.5061/dryad.x95x69pj8">http://dx.doi.org/10.5061/dryad.x95x69pj8</ext-link><comment>Dryad Digital Repository, doi:10.5061/dryad.x95x69pj8</comment></element-citation><element-citation id="dataset2" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>Vasileva E</collab><collab>Warren M</collab><collab>Triche T</collab><collab>Amatruda J</collab></person-group><year iso-8601-date="2021">2021</year><source>Proteomics analysis of normal and EWSR1-FLI1-expressing embryos/tissue</source><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.5061/dryad.x95x69pj8">https://doi.org/10.5061/dryad.x95x69pj8</ext-link><comment>Dryad Digital Repository, doi:10.5061/dryad.x95x69pj8</comment></element-citation></p><p>The following previously published datasets were used:</p><p><element-citation id="dataset3" publication-type="data" specific-use="references"><person-group person-group-type="author"><collab>Savola S</collab><collab>Klami A</collab><collab>Myllykangas S</collab><collab>Manara C</collab><collab>Scotlandi K</collab><collab>Picci P</collab><collab>Knuutila S</collab><collab>Vakkila J</collab></person-group><year iso-8601-date="2009">2009</year><source>Inflammatory gene profiling of Ewing sarcoma family of tumors (set B)</source><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE17674">https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE17674</ext-link><comment>NCBI Gene Expression Omnibus, GSE17674</comment></element-citation><element-citation id="dataset4" publication-type="data" specific-use="references"><person-group person-group-type="author"><collab>Khan J</collab><collab>Shern J</collab><collab>Langenau D</collab></person-group><year iso-8601-date="2017">2017</year><source>Gene Expression in Human Rhabdomyosarcoma</source><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE108022">https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE108022</ext-link><comment>NCBI Gene Expression Omnibus, GSE108022</comment></element-citation></p></sec><supplementary-material><ext-link xlink:href="elife-69734-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>